In the future, a reference price group will be formed of interchangeable medicinal products if the reference price group includes at least two reimbursable medicinal products on the market, at least one of which is a generic product, parallel imported medicinal product or parallel distributed product. Provisions on the criteria for determining reference price groups are laid down in the Health Insurance Act and on interchangeable medicinal products in the Medicines Act.
During the reference price period starting in April 2023, a reference price group will no longer be formed if the group contains only one reimbursable medicinal product available on the market. The reimbursement status and wholesale price of medicinal products included in such a reference price group are valid for a maximum of one year from the end of the reference price group (so-called transition period). During the transition period, the holder of the marketing authorisation must submit an application for reimbursement status and wholesale price to the Pharmaceuticals Pricing Board if it wants the medicinal product to be reimbursed also after the transition period. During the transition period, the holder of the marketing authorisation must also submit a price notification on a quarterly basis in order to maintain the reimbursement status.
The list of medicinal products in the transition period will be published on the website of the Pharmaceuticals Pricing Board.
More information
Hanna-Kaisa Joutsen, Pharmaceutical Officer, firstname.lastname@gov.fi
Ulla Kurkijärvi, Principal Pharmaceutical Officer, firstname.lastname@gov.fi